76
Participants
Start Date
October 16, 2017
Primary Completion Date
August 26, 2019
Study Completion Date
September 28, 2019
Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)
2 capsules taken once daily
Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)
2 capsules taken once daily
Placebo
2 capsules taken once daily
Beth Israel Medical Center, New York
Albany Medical College, Albany
University of Pennsylvania, Philadelphia
John Hopkins University, Baltimore
University of Virginia, Charlottesville
Duke University Medical Center, Durham
Medical University of South Carolina, Charleston
University of Florida, Gainesville
University of South Florida, Tampa
Cleveland Clinic, Cleveland
University of Cincinnati, Cincinnati
University of Michigan, Ann Arbor
Michigan State University, East Lansing
Medical College of Wisconsin, Milwaukee
Rush University Medical Center, Chicago
Baylor College of Medicine, Houston
University of Colorado at Denver, Aurora
Barrow Neurological Institute, Sun City
Cleveland Clinic - Las Vegas, Las Vegas
University of California Davis, Sacramento
Oregon Health and Science University, Portland
Inland Northwest Research, Spokane
University of Alabama at Birmingham, Birmingham
Massachusetts General Hospital, Boston
University of Rochester
OTHER
University of Iowa
OTHER
Michael J. Fox Foundation for Parkinson's Research
OTHER
Northwestern University
OTHER